The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-03-05
DOI
10.3389/fonc.2019.00129
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter
- (2018) Masaru Watanabe et al. CANCER SCIENCE
- Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer
- (2018) Dana Wai Yi Tsui et al. EMBO Molecular Medicine
- Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
- (2018) Jason D. Merker et al. JOURNAL OF CLINICAL ONCOLOGY
- Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR -Mutated NSCLC
- (2018) Anna Buder et al. Journal of Thoracic Oncology
- IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC)
- (2018) Christian Rolfo et al. Journal of Thoracic Oncology
- GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors
- (2018) Junhong Jiang et al. LUNG CANCER
- PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab
- (2018) Nicolas Guibert et al. LUNG CANCER
- Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy
- (2018) R. Minari et al. LUNG CANCER
- Detection and localization of surgically resectable cancers with a multi-analyte blood test
- (2018) Joshua D. Cohen et al. SCIENCE
- The role of liquid biopsy in predicting post-operative recurrence of non-small cell lung cancer
- (2018) Hengrui Liang et al. Journal of Thoracic Disease
- Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer
- (2018) Galatea Kallergi et al. Therapeutic Advances in Medical Oncology
- Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report
- (2018) Zhang Ling et al. Cancer Biology & Medicine
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer
- (2018) Smadar Laufer-Geva et al. Journal of Thoracic Oncology
- The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review
- (2018) Bao-Dong Qin et al. OncoTargets and Therapy
- Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers†
- (2017) Clara I. Bayarri-Lara et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- The liquid biopsy: a tool for a combined diagnostic and theranostic approach for care of a patient with late-stage lung carcinoma presenting with bilateral ocular metastases
- (2017) Linda Bouhlel et al. Expert Review of Anticancer Therapy
- Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer
- (2017) Jinfeng He et al. Future Oncology
- Liquid biopsy: A potential and promising diagnostic tool for advanced stage non-small cell lung cancer patients
- (2017) DC Doval et al. INDIAN JOURNAL OF CANCER
- Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management
- (2017) Julie Vendrell et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Validation of the SHOX2 / PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease
- (2017) Gunter Weiss et al. Journal of Thoracic Oncology
- Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
- (2017) Sai-Hong Ignatius Ou et al. LUNG CANCER
- Liquid biopsy: a step forward towards precision medicine in urologic malignancies
- (2017) Ashley Di Meo et al. Molecular Cancer
- Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients
- (2017) Qian Yu et al. Molecular Medicine Reports
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
- (2017) Christopher Abbosh et al. NATURE
- Integrating liquid biopsies into the management of cancer
- (2017) Giulia Siravegna et al. Nature Reviews Clinical Oncology
- Current approaches for avoiding the limitations of circulating tumor cells detection methods—implications for diagnosis and treatment of patients with solid tumors
- (2017) Artur Kowalik et al. Translational Research
- EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial
- (2017) Jana Fassunke et al. VIRCHOWS ARCHIV
- Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
- (2017) Marcin Skrzypski et al. Wspolczesna Onkologia-Contemporary Oncology
- Dynamic monitoring of EGFR mutations in circulating cell-free DNA for EGFR-mutant metastatic patients with lung cancer: Early detection of drug resistance and prognostic significance
- (2017) Jianjiao Ni et al. Oncology Letters
- Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis
- (2017) Chang Gon Kim et al. Oncotarget
- Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment
- (2017) Mariano Provencio et al. Oncotarget
- Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients
- (2017) Mariano Provencio et al. Oncotarget
- Analyzing epidermal growth factor receptor mutation status changes in advanced non-small-cell lung cancer at different sampling time-points of blood within one day
- (2017) Jin Wang et al. Thoracic Cancer
- Liquid biopsy: A potential and promising diagnostic tool for advanced stage non-small cell lung cancer patients
- (2017) DC Doval et al. INDIAN JOURNAL OF CANCER
- Urine test for EGFR analysis in patients with non-small cell lung cancer
- (2017) Aleksandra Franovic et al. Journal of Thoracic Disease
- Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC).
- (2017) C. Zhou et al. JOURNAL OF CLINICAL ONCOLOGY
- Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive forEGFRactivating mutations
- (2016) E. Iwama et al. ANNALS OF ONCOLOGY
- Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) S. Novello et al. ANNALS OF ONCOLOGY
- Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society
- (2016) Lynette M. Sholl et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs
- (2016) S. Chen et al. Clinical & Translational Oncology
- Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker
- (2016) Daniel Pietrasz et al. CLINICAL CANCER RESEARCH
- Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
- (2016) Jeanne Tie et al. Science Translational Medicine
- KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies
- (2016) Wei Pan et al. Oncotarget
- Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer
- (2016) Shaohua Cui et al. Oncotarget
- Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer
- (2016) Victoria Villaflor et al. Oncotarget
- Circulating tumor DNA detection in lung cancer patients before and after surgery
- (2016) Nannan Guo et al. Scientific Reports
- Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer
- (2016) Adrian G. Sacher et al. JAMA Oncology
- Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
- (2015) T. Mok et al. CLINICAL CANCER RESEARCH
- Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease
- (2015) Eleonor Olsson et al. EMBO Molecular Medicine
- Circulating free DNA concentration is an independent prognostic biomarker in lung cancer
- (2015) Claire Tissot et al. EUROPEAN RESPIRATORY JOURNAL
- Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery
- (2015) Thomas Reinert et al. GUT
- The 2015 World Health Organization Classification of Lung Tumors
- (2015) William D. Travis et al. Journal of Thoracic Oncology
- Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
- (2015) Isaac Garcia-Murillas et al. Science Translational Medicine
- Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts
- (2014) S Li et al. BRITISH JOURNAL OF CANCER
- Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib
- (2014) Boe S. Sorensen et al. CANCER
- Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
- (2014) R. Katayama et al. CLINICAL CANCER RESEARCH
- Across the Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer
- (2014) Sheila Piva et al. CURRENT PHARMACEUTICAL DESIGN
- Liquid Biopsies: Genotyping Circulating Tumor DNA
- (2014) Luis A. Diaz et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma
- (2014) Min Hwan Kim et al. LUNG CANCER
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment
- (2014) Antonio Marchetti et al. PLoS One
- Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer
- (2013) S. Cardarella et al. CLINICAL CANCER RESEARCH
- Epithelial-mesenchymal plasticity in carcinoma metastasis
- (2013) J. H. Tsai et al. GENES & DEVELOPMENT
- Prognostic Value of Tumor Markers, NSE, CA125 and SCC, in Operable NSCLC Patients
- (2013) Dangfan Yu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR mutation frequency and effectiveness of erlotinib: A prospective observational study in Danish patients with non-small cell lung cancer
- (2013) Britta Weber et al. LUNG CANCER
- Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay
- (2013) Irène Baccelli et al. NATURE BIOTECHNOLOGY
- The quest to overcome resistance to EGFR-targeted therapies in cancer
- (2013) Curtis R Chong et al. NATURE MEDICINE
- Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis?
- (2013) Evelyn Kidess et al. Genome Medicine
- Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation—diversity, ductility, and destiny
- (2012) Kenichi Suda et al. CANCER AND METASTASIS REVIEWS
- Heading off with the herd: how cancer cells might maneuver supernumerary centrosomes for directional migration
- (2012) Angela Ogden et al. CANCER AND METASTASIS REVIEWS
- KRAS Mutations in Lung Cancer
- (2012) Niki Karachaliou et al. Clinical Lung Cancer
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
- (2011) Hiroyuki Yasuda et al. LANCET ONCOLOGY
- Carcinoembryonic antigen (CEA) as tumor marker in lung cancer
- (2011) M. Grunnet et al. LUNG CANCER
- Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature
- (2011) Digant Gupta et al. Nutrition Journal
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene
- (2009) Tsuyoshi Takahashi et al. ANNALS OF SURGICAL ONCOLOGY
- TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS
- (2009) Daisy Wing-Sze Wong et al. CANCER
- COPD prevalence is increased in lung cancer, independent of age, sex and smoking history
- (2009) R. P. Young et al. EUROPEAN RESPIRATORY JOURNAL
- EGFR testing in lung cancer is ready for prime time
- (2009) Fred R Hirsch et al. LANCET ONCOLOGY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology and young onset
- (2009) Kentaro Inamura et al. MODERN PATHOLOGY
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- (2009) Rafael Rosell et al. NEW ENGLAND JOURNAL OF MEDICINE
- EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
- (2008) J. P. Koivunen et al. CLINICAL CANCER RESEARCH
- EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas
- (2008) Kazuya Shinmura et al. LUNG CANCER
- Circulating mutant DNA to assess tumor dynamics
- (2008) Frank Diehl et al. NATURE MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now